Park Yong-Doo, Kim So-yeon, Lyou You-Jeong, Lee Dong-Youn, Yang Jun-Mo
Department of Dermatology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea.
Biochem Cell Biol. 2006 Feb;84(1):112-6. doi: 10.1139/o05-151.
Research involving whitening agents requires several steps of experimentation, and the initial step is to test whitening agents with human melanocytes and those with human tyrosinase. Unfortunately, it takes a long time to gather human melanocytes, and these cells have some limitations when it comes to performing experiments, such as their passage difficulties and their cost. In this study, we suggest that the TXM13 human melanoma cells could be a useful cell candidate for studying human tyrosinase inhibition and depigmentation. We applied a tyrosinase inhibitor, such as dithioglycerine (DTGC), to validate the cell line's usefulness, and we tested the effect of DTGC on TXM13 melanogenesis. The results showed that human tyrosinase from TXM13 was appropriate, according to the inhibition kinetics, and that the conspicuous depigmentation of TXM13 occurred after DTGC treatment without downregulating the tyrosinase expression level. When taken together, our findings provide useful information regarding the use of the TXM13 melanoma cells for the development of whitening agents.
涉及美白剂的研究需要几个实验步骤，第一步是用人黑素细胞和人酪氨酸酶测试美白剂。不幸的是，收集人黑素细胞需要很长时间，而且这些细胞在进行实验时存在一些局限性，比如传代困难和成本问题。在本研究中，我们认为TXM13人黑色素瘤细胞可能是研究人酪氨酸酶抑制和色素沉着的有用细胞候选物。我们应用了一种酪氨酸酶抑制剂，如二硫代甘油（DTGC），来验证该细胞系的实用性，并测试了DTGC对TXM13黑色素生成的影响。结果表明，根据抑制动力学，TXM13中的人酪氨酸酶是合适的，并且在DTGC处理后，TXM13出现了明显的色素脱失，而酪氨酸酶表达水平并未下调。综上所述，我们的研究结果为TXM13黑色素瘤细胞用于美白剂开发提供了有用信息。
